Skip to main content
Woman in lab coat and protecting cap with eye glasses.


Our focus

The WATCHMAN FLX™ Implant is built on the most studied and implanted left atrial appendage closure device in the world, designed to advance procedural performance and safety.

Linda’s story

We’re committed to advancing stroke prevention therapy through a one-time, minimally invasive procedure that permanently reduces stroke risk for people with non-valvular atrial fibrillation.

Delivering meaningful innovation

A pioneering alternative to blood thinners.

The WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Implant is indicated to reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) who need an alternative to oral anticoagulation therapy by permanently closing off the left atrial appendage – the area of the heart where stroke-causing blood clots commonly form. This technology, which is built upon the most studied and implanted LAAC device in the world, features a new, fully rounded design that offers physicians the ability to safely enter, and maneuver within, the left atrial appendage.

check icon

With 20 years of clinical trial and real-world experience - including 10+ clinical trials – The WATCHMAN Implant has a proven safety record.

check icon

The WATCHMAN Implant has a high implant success* rate of 99% and a low major complication rate** of 0.5%.¹

check icon

In a clinical trial, 96% of people were able to stop taking blood thinners 45 days after getting a WATCHMAN FLX Implant.¹

Conditions we treat

  • Stroke risk reduction for non-valvular atrial fibrillation


patients with atrial fibrillation globally.2


patients with atrial fibrillation in the U.S.3


This population is 5x more likely to have a stroke.4


of stroke-causing clots that come from the heart are formed in the LAA.5

Solutions we offer

  • Left Atrial Appendage Closure with WATCHMAN FLX™

Product spotlights


  1. Reference: Kar, S., et al, Primary Outcome Evaluation of the Next Generation LAAC Device: Results from the PINNACLE FLX Trial, Circulation, 2021.
  2. Lippi G, Sanchis-Gomar F., et al. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2021; Feb 16:217-221. 
  3. Colilla S, Crow A et al. Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population. Am J Cardiol 2013;112:1142-1147. 
  4. Holmes, DR. et al. Seminars in Neurology, 2010; 30:528-536. 
  5. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61:755-759

*Procedure success defined as successful delivery and release of a WATCHMAN FLX device into the LAA.

** In a post FDA approval analysis. Major complication is defined as an occurrence of one of the following events between the time of implant and within 7 days following the procedure or by hospital discharge, whichever is later: all-cause death, ischemic stroke, systemic embolism, or device or procedure related events requiring open cardiac surgery or major endovascular intervention.